2023-05-10 07:32:55 ET
- Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q1 GAAP EPS of -$0.85 beats by $0.20 .
- Revenue of $3M (-45.2% Y/Y) misses by $0.3M .
-
Cash, cash equivalents and marketable securities as of March 31, 2023 were $166 million, as compared with $202 million on December 31, 2022.
-
Based on its current plans, Syros believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into 2025, beyond pivotal Phase 3 data from the SELECT-MDS-1 trial and initial data from the randomized portion of the SELECT-AML-1 trial.
For further details see:
Syros Pharmaceuticals GAAP EPS of -$0.85 beats by $0.20, revenue of $3M misses by $0.3M